All In Biotech

Drug Trial Radar · NCT06555237

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies (MEKinRAS) - Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Aug 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Medical University of WarsawAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 day, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.

Conditions

  • Cardiomegaly
  • Noonan Syndrome

Interventions

  • Trametinib tabletDrug

    Trametynib orally once daily in 0,025mg/kg dose

  • Standard therapyDrug

    Disopiramide and Beta blockers orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness of the trametynib treatment on cardiac hyperthropyTime frame: 1 year
  2. Effectiveness of the trametynib treatment on laboratory enzymes levelsTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Paediatrics, The Medical University of Warsaw, Poland

    Warsaw, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.